Trying to separate three different claims about GHK-Cu: that it is the right molecule, that it is the right dose, and that it does something useful.
What surprised me is how much of the perceived benefit was routine and attention rather than pharmacology.
Tolerance and underdosing look identical from the inside, which is why the answer is usually a blood test and not more forums.
The comparison group matters more than the compound when the outcome is something as fuzzy as focus.
Injection site reactions are trivial until they are not, and a fresh needling technique removes half of them.
What is the strongest human evidence anyone here has actually read, not skimmed?
My rule, after years of this: if it cannot survive being written down with the numbers attached, it is marketing.
Baseline first. Without a baseline the after picture is decoration.
Is a baseline blood test really necessary before starting something like this?
Stupid question: how do you know whether what is in the vial matches the label at all? Same for me with GHK-Cu, unfortunately.
Narrow conclusion, briefly right. Broad conclusion, interestingly wrong. I know which I keep choosing.
Is a baseline blood test really necessary before starting something like this?
Loose evidence is not nothing, but a washout either side is the only reason to trust your own take.
Where does the human data stop and the extrapolation begin? That is the whole thread. Same for me with GHK-Cu, unfortunately.
Three questions kill most of the confidence in a thread like this: sample size, blinding, who paid. Injection site reaction was my main issue with GHK-Cu too.
A certificate of analysis answers one question and gets quoted as though it answers four. Three weeks in on GHK-Cu and it lines up.